Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 出版: |
2014
|
| _version_ | 1826269815698882560 |
|---|---|
| author | Hillmen, P Pettitt, A Schuh, A Milligan, D Bowles, K Bareford, D Riaz, J Follows, G Rule, S Wallis, J Gribben, J Noble, R Pocock, C Lisby, S Carey, J Gupta, I Chang, C McKeown, A |
| author_facet | Hillmen, P Pettitt, A Schuh, A Milligan, D Bowles, K Bareford, D Riaz, J Follows, G Rule, S Wallis, J Gribben, J Noble, R Pocock, C Lisby, S Carey, J Gupta, I Chang, C McKeown, A |
| author_sort | Hillmen, P |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T21:31:04Z |
| format | Journal article |
| id | oxford-uuid:44b0425e-a67e-4d5f-b1f0-078af8b28a19 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:31:04Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:44b0425e-a67e-4d5f-b1f0-078af8b28a192022-03-26T15:03:14ZOfatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:44b0425e-a67e-4d5f-b1f0-078af8b28a19Symplectic Elements at Oxford2014Hillmen, PPettitt, ASchuh, AMilligan, DBowles, KBareford, DRiaz, JFollows, GRule, SWallis, JGribben, JNoble, RPocock, CLisby, SCarey, JGupta, IChang, CMcKeown, A |
| spellingShingle | Hillmen, P Pettitt, A Schuh, A Milligan, D Bowles, K Bareford, D Riaz, J Follows, G Rule, S Wallis, J Gribben, J Noble, R Pocock, C Lisby, S Carey, J Gupta, I Chang, C McKeown, A Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title | Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title_full | Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title_fullStr | Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title_full_unstemmed | Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title_short | Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) |
| title_sort | ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia cll results of the phase iii study complement 1 omb110911 ncrn adopted |
| work_keys_str_mv | AT hillmenp ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT pettitta ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT schuha ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT milligand ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT bowlesk ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT barefordd ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT riazj ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT followsg ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT rules ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT wallisj ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT gribbenj ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT nobler ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT pocockc ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT lisbys ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT careyj ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT guptai ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT changc ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted AT mckeowna ofatumumabpluschlorambucilversuschlorambucilaloneinpatientswithuntreatedchroniclymphocyticleukaemiacllresultsofthephaseiiistudycomplement1omb110911ncrnadopted |